MOGAD is a distinct diagnosis, not simply AQP4-negative NMOSD
Heidelberg and Freiburg explicitly distinguish MOGAD from NMOSD and multiple sclerosis. The phenotype can include optic neuritis, myelitis, brainstem inflammation and ADEM-like or other inflammatory CNS presentations. Correct classification matters because prognosis and long-term treatment strategy differ.
- Optic neuritis, including recurrent attacks
- Spinal-cord inflammation / myelitis
- Brainstem inflammatory syndromes
- ADEM-like presentations, particularly in younger patients
- Other compatible inflammatory demyelinating CNS syndromes
MOG-IgG testing must be interpreted with the clinical phenotype
Heidelberg has specialist expertise in MOG-IgG antibody diagnostics and assay development. A laboratory result should be interpreted together with symptoms and imaging rather than used as a stand-alone explanation for nonspecific neurological complaints. When the clinical pattern is atypical, specialist review should reconsider MS, AQP4-NMOSD and other inflammatory, infectious or vascular mimics.
MRI and CSF help define the attack and exclude alternatives
Heidelberg's MOGAD pathway includes neurological examination, serum MOG antibody testing, MRI of the brain and spinal cord, CSF analysis and electrophysiological testing. For optic neuritis, orbital imaging and ophthalmological or neuro-ophthalmological assessment may also be relevant. International patients should provide original imaging when requested, not only reports.
Acute attacks are time-sensitive
Heidelberg describes acute MOGAD attacks as being treated with high-dose intravenous corticosteroids over several days or, alternatively or when clinically necessary, with a blood-wash/apheresis procedure. Sudden visual loss, rapidly progressive weakness, new severe gait impairment or other acute neurological deficits require urgent local treatment rather than waiting for planned international travel.
Not every patient needs the same long-term preventive strategy
Some patients experience a single attack while others relapse. Heidelberg notes that relapse-prevention treatment can use therapies targeting antibody-producing immune cells or other immunosuppressive approaches. The decision should consider relapse history, residual disability, age, infection risk, pregnancy plans, prior treatment response and whether the diagnosis remains secure.
Persistent MOG-IgG does not replace clinical follow-up
Antibody status can contribute to specialist assessment, but long-term decisions should also reflect attacks, recovery, neurological examination, visual function and MRI. Heidelberg describes regular clinical and laboratory monitoring during long-term immunotherapy, with interval imaging as appropriate.
Complex or treatment-refractory cases benefit from interdisciplinary review
Freiburg's inflammatory-CNS clinic provides first diagnosis, differential diagnosis, second opinions and immunotherapy escalation for MOGAD. Its Neuroimmunboard specifically discusses difficult MOGAD and NMOSD therapy changes with neurology, neuroradiology and rheumatology input.
What to send for a German MOGAD second opinion
A useful record package should document why MOGAD was diagnosed, what each attack looked like and how completely the patient recovered.
- Neurology and neuroimmunology reports
- MOG-IgG result including assay, titer or laboratory details when available
- AQP4-IgG result
- Brain, orbital and spinal-cord MRI in DICOM format when requested
- CSF results
- Ophthalmology, OCT or visual-evoked-potential reports when optic neuritis occurred
- Timeline of attacks and recovery
- Previous high-dose steroid or apheresis treatment
- Current and previous preventive immunotherapy
- A specific question: confirm MOGAD, distinguish it from MS/NMOSD, review relapse treatment or decide whether long-term prevention is justified
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- MOG-IgG-associated encephalomyelitis / MOGAD — Heidelberg University Hospital ↗
- MOGAD antibody diagnostics and research — Heidelberg University Hospital ↗
- Inflammatory CNS diseases outpatient clinic — University Medical Center Freiburg ↗
- Neuroimmunboard – complex MOGAD therapy decisions — University Medical Center Freiburg ↗